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Available online 10 March 2016Bioenergetics and bioenergetic-related functions are altered in Alzheimer's disease (AD) subjects. These alter-
ations represent therapeutic targets and provide an underlying rationale for modifying brain bioenergetics in
AD-affected persons. Preclinical studies in cultured cells and mice found that administering oxaloacetate
(OAA), a Krebs cycle and gluconeogenesis intermediate, enhanced bioenergetic ﬂuxes and upregulated some
brain bioenergetic infrastructure-related parameters. We therefore conducted a study to provide initial data on
the tolerability and pharmacokinetics of OAA in AD subjects. Six AD subjects received OAA 100 mg capsules
twice a day for one month. The intervention was well-tolerated. Blood level measurements following ingestion
of a 100 mg OAA capsule showed modest increases in OAA concentrations, but pharmacokinetic analyses were
complicated by relatively high amounts of endogenous OAA. We conclude that OAA 100 mg capsules twice per
day for one month are safe in AD subjects but do not result in a consistent and clear increase in the OAA blood
level, thus necessitating future clinical studies to evaluate higher doses.







Alzheimer's disease (AD) is clinically characterized by cognitive de-
cline [1]. While hypotheses postulate its potential causes and propose
various therapeutic targets, no clearly effective disease-modifying inter-
ventions are currently recognized.
The single greatest AD risk factor is advancing age. Brain bioener-
getic function and mitochondrial integrity decline with advancing age
and to a further extent when AD is present [2]. Energy metabolism-
associated changes in AD include decreased glucose utilization, as indi-
cated byﬂuoro-deoxyglucose positron emission tomography (FDGPET)
studies that reliably reveal early and neuroanatomically predictablelzheimer's Disease Assessment
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. This is an open access article underhypometabolic brain regions [3–5]. Activities of several mitochondria-
localized enzymes, including enzymes of the Krebs cycle and the respi-
ratory chain, are also reduced in AD subject brains and in some cases
even peripheral tissues [2]. Some brain regions show an overall reduc-
tion in the number of normal-appearing mitochondria, apparently in-
creased mitochondrial debris in autophagosomes, and low levels of
the mitochondrial biogenesis-promoting peroxisome proliferator-
activated receptor gamma coactivator (PGC1α) protein [6,7]. Some AD
investigators believe energy metabolism functional and structural
changes may contribute to the progression of disease and perhaps
even initiate it, and constitute reasonable therapeutic targets [8,9].
We previously reported changes in bioenergetic ﬂuxes and infra-
structure when cells or animals are exposed to various energy me-
tabolism pathway intermediates. One intermediate we evaluated is
oxaloacetate (OAA), a dicarboxylic acid found in Krebs cycle and glu-
coneogenesis ﬂuxes. Administering OAA to cultured neuronal SH-
SY5Y cells enhances glycolysis and respiratory ﬂuxes, increases
PGC1α mRNA and protein, and increases mRNA and protein levels of
a mitochondrial DNA (mtDNA)-encoded cytochrome oxidase (COX)
subunit [10]. The brains of mice that received a two-week course of in-
traperitoneal (IP) OAA showed increased levels of PGC1αmRNA, an in-
crease in the nuclear to cytosolic PGC1α protein ratio, and higher
amounts of the COX subunit 4 protein [11]. Compared to saline injectedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pal neurogenesis activity and changes suggesting enhanced brain insu-
lin signaling and reduced neuroinﬂammation [11]. For these reasonswe
want to determine the effects of OAA on persons with AD.
2. Methods
This study was approved by the Kansas University Medical Center
Human Subjects Committee and informed consent was obtained for
all subjects. We recruited six AD subjects from the University of Kansas
Alzheimer's Disease Center (KU ADC) Clinical Core cohort; APOE
genotype status and clinical dementia rating scale (CDR) scores are in-
dependently acquired for KU ADC cohort members. Subjects met the
McKhann et al. AD criteria [12], had CDR scores of 0.5 or 1, and had
mini-mental state exam (MMSE) scores between 15 and 28. Subjects
with a syndromic diagnosis of mild cognitive impairment (as opposed
to a full AD diagnosis), as well as subjects with diabetes, were excluded.
Each subject had a study partnerwhowas already engaged in their daily
social and medical care.
OAA capsules were obtained from Terra Biological LLC (San Diego,
California). Terra Biological LLC markets OAA capsules produced using
good manufacturing practice procedures, and OAA batches used to pre-
pare these capsules are tested to ensure the integrity of the OAA. The
capsules contained 100 mg OAA and 150 mg of ascorbic acid. Because
100 mg of OAA was the lowest amount that could be administered at
a given time, we predicted OAA would elevate the blood level for a lim-
ited period, and safety was a major focus of this study OAA dosing was
set at 100 mg twice per day.
Participation in the study required two study visits, an initial visit
and a ﬁnal study visit 4 weeks later (Fig. 1). For both visits a 36 item re-
view of symptoms inventory was also completed by the subject and the
study partner. During the initial visit the ﬁrst 100 mg OAA capsule was
administered and subject assessments were performed. At the conclu-
sion of the initial visit a bottle containing 60OAA capsuleswas provided
with instructions for the subject to take one capsule each morning and
one capsule each evening. Approximately one month later the ﬁnal
study visit was conducted, at which time subjects were assessed at the
timeof taking their ﬁnal 100mgOAA capsule. TheOAA bottleswere col-
lected and any remaining capsules were counted to assess compliance.
For each visit subjects presented at 8 AM to the Clinical Trials Unit of
the Kansas University Medical Center having fasted since midnight. TheFig. 1. Pharmacokinetics of Oxaloacetate (POX) study organization.subjects were weighed and vital signs determined. A heparin lock was
inserted, and blood was obtained to determine the subject's complete
blood count (CBC), electrolytes, liver function tests (LFTs), plasma
amino acids, and insulin level. A 3–5ml baseline blood sample for phar-
macokinetic (PK) testingwas then obtained, and a 100mgOAA capsule
was orally administered with 200 ml of water. Additional 3–5 ml PK
blood samples were obtained at 30, 45, 60, 75, 90, 105, 120, 135, 150,
and 240 min after dosing. The PK blood samples were immediately
placed on ice and processed into plasma within 10 min of acquisition.
Aliquots of plasma (0.5 ml each) were frozen immediately and
stored at −80 °C until analysis. During the time lag between the
150 and 240 min PK phlebotomies, a psychometrician administered
an MMSE and Alzheimer's Disease Assessment Scale-Cognitive sub-
scale (ADASCog) test to each subject. The ADASCog version in our
study is the version used by the Alzheimer's Disease Cooperative
Study Group, which scores 11 items. Higher scores indicate worse
performance and the highest maximum possible score is 70 points.
Quantitation of OAA in plasma was performed using 3 different
approaches. We used a commercially available coupled enzyme
method assay kit (Sigma-Aldrich, St. Louis, MO) that utilizes a ﬂuo-
rescence detection protocol to measure OAA concentrations. This
kit also provides an absorption-based protocol for OAA measure-
ments, and the absorption-based approach was used as well. Finally,
because OAA undergoes some degree of decarboxylation to pyruvate
when it is placed in solution, we adapted and applied a liquid chro-
matography–tandem mass spectrometry (LC–MS/MS)-based assay
for OAA quantitation and to measure plasma pyruvate concentra-
tions [13].
The glucose and insulin levels from each visit were used to calculate
the homeostatic model assessment of insulin resistance (HOMA-IR)
values for each subject using the following equation: (glucose in mg/
dl x insulin inmcu/ml)/405. Initial and ﬁnal visit HOMA-IR,weight, plas-
ma amino acid, and cognitive score values were compared using a
paired t-test approach. CBC, electrolyte, and LFT studies were analyzed
for the appearance of clinical abnormalities.
3. Results
Subject characteristics are shown in Table 1. Mean age (with stan-
dard deviation)was 76.2±8.2. Only one subject lacked anAPOE4 allele.
All of the subjects completed the study. During the course of the study
no adverse events, treatment-induced symptoms, or clinically signiﬁ-
cant changes in safety labs were observed. Compliance estimates for
the six subjects ranged from 76 to 100% (Table 2).
Weight, fasting glucose, fasting insulin, andHOMA-IR values for sub-
jects varied between visits, but as a group no consistent changes in
weight or HOMA-IR were observed during the course of the study
(Table 3). Although there was not a statistically signiﬁcant reduction
in post-treatment fasting glucose levels, post-treatment fasting glucose
levels were slightly lower than pre-treatment levels in 5 of the 6 sub-
jects. MMSE and ADASCog values also varied between visits, but as a
group no consistent changes in the MMSE or ADASCog scores were ob-
served during the course of the study (Table 3). The average visit 1 and 2
MMSE scores (with standard deviations) were, respectively, 21.2 ± 4.7
and 19.5 ± 5.9. The average visit 1 and visit 2 ADASCog scores were
21.5 ± 5.1 and 23.7 ± 6.6 (Table 3).Table 1
Subject characteristics.
Subject Age Sex APOE CDR
1 64 M 4/4 0.5
2 68 M 3/4 1
3 78 M 3/3 1
4 83 F 3/4 0.5
5 82 F 3/4 1
6 82 M 3/4 1
Table 2
Compliance and safety.
Subject Compliance New symptoms Clinically signiﬁcant
abnormal safety labs
1 89% None reported None
2 98% None reported None
3 100% None reported None
4 82% None reported None
5 76% None reported None
6 98% None reported None
Table 4
Plasma amino acid measurements. V1 = visit 1; V2 = visit 2.
Subject Glutamate Aspartate Alanine
V1 V2 V1 V2 V1 V2
1 29 45 1 3 451 343
2 74 51 4 3 562 617
3 50 49 2 3 326 479
4 20 16 2 2 261 285
5 27 33 2 2 474 374
6 36 43 2 2 338 407
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Clinical Labs and includedmeasurements of 42 amino acids and deriva-
tives. Values from the visit 1 and 2 values were compared, and using a p
value cut-off of 0.05 no statistically signiﬁcant inter-visit differences
were observed (Table 4). Values for two amino acids (glutamate and as-
partate) most directly linked to OAA metabolism (as glutamate reacts
with OAA to from aspartate and α-ketoglutarate) did not show statisti-
cally signiﬁcant inter-visit changes. Levels of alanine, which is in equi-
librium with pyruvate (a decarboxylation product of OAA), also did
not change across the visits (Table 4).
For PK measurements performed using the enzymatic-based OAA
quantiﬁcation kit, the more sensitive ﬂuorescence-based approach
was confounded either by plasma auto-ﬂuorescence at the critical exci-
tation/emission wavelengths or else through a non-speciﬁc, activating
interaction between plasma and kit components. No useful data were
obtained using this approach. The kit's absorbance-based approach
was therefore utilized. The absorbancemethod has a ten-fold reduction
in sensitivity as compared to the ﬂuorescence assay, and the levels of
OAA detected were very near the limit of detection for the method.
Qualitative review of some of the data from this analysis indicates a pos-
sible Tmax peak occurs between 1 and 1.5 h after ingestion of a 100 mg
capsule (data not shown). This pattern, though,wasnot consistently ob-
served across subjects.
The attempts to measure OAA by the coupled enzyme assay con-
sumed the acquired plasma samples from subject 2. Plasma samples
for the remaining 5 subjects were analyzed by LC–MS/MS for both
OAA and pyruvate. OAA concentrations for subject 1 were at or below
our limit of quantitation (10 ng/ml), so the results from that patient
were not included in the determination of PK parameters. All subjects
showed quantiﬁable pyruvate concentrations.
Representative PK data are shown in Fig. 2. The plasma concentra-
tion versus time plots in the ﬁgure does not show typical PK behavior.
The pre-dose OAA concentrations were about 60% of the observed
Cmax for the ﬁrst dose of OAA, and the pre-dose concentration and
Cmaxwere virtually identical for the Day 28 dose. Neither day exhibited
the expected absorption and clearance phases in the time course. It is
also apparent that for this subject no accumulation of OAAwas seen fol-
lowing the 28 days of dosing. The compiled observations for OAA and
pyruvate for the LC–MS/MS-analyzed subjects are shown in Table 5. It
is apparent that Cmax and Tmax values were quite variable, but it is
important to note that the Tmax for OAA was centered on 1.2 h after
dosing. The ratio of Cmax to the pre-dose OAA concentration (C0)Table 3
Weight, fasting glucose, fasting insulin, HOMA-IR, MMSE, and ADASCog data. V1= visit 1;
V2 = visit 2.
Subject Weight
(kg)
Glucose Insulin HOMA-IR MMSE ADASCog
V1 V2 V1 V2 V1 V2 V1 V2 V1 V2 V1 V2
1 72.9 74.3 105 104 7.2 6.9 1.87 1.77 28 28 15 18
2 86.2 83.5 107 101 25.5 14.6 6.73 3.64 21 18 23 28
3 78.3 81.1 104 100 21.2 24.1 5.44 5.95 25 25 17 14
4 70.0 68.1 99 91 6.4 5.5 1.56 1.24 18 12 26 28
5 88.4 87.6 140 124 10.0 6.7 3.46 2.05 15 18 28 23
6 76.4 78.1 100 105 2.8 3.9 0.69 1.01 20 16 20 31underscores that the increases in plasma OAA concentrations following
this 100 mg dose were quite small relative to the observed basal con-
centrations. Our observations for possible effects on pyruvate concen-
trations mirrored the results seen for OAA, with the exception of a
later Tmax (2.6 h).
4. Discussion
Over a one month period 100 mg of OAA, taken twice per day, was
well tolerated by AD subjects and appeared to be safe. Cognitive perfor-
mance did not improve over the 1-month treatment period, although it
must be noted that this study was neither designed nor intended to re-
veal changes in cognitive performance. Indeed, the initial visit cognitive
data were obtained after subjects had taken their ﬁrst OAA capsule.
The 100 mg dose did not yield consistent changes in either OAA or
pyruvate levels. Our ability to detect consistent changes was likely hin-
dered by high background levels of OAA and pyruvate, whichmay have
obscured genuine treatment-induced changes. Regardless, our data sug-
gest 100 mg of OAA does not signiﬁcantly change an individual AD
subject's plasma level. Failure to detect any reliable treatment-induced
amino acid changes is potentially consistent with but does not prove
this possibility.Fig. 2.OAAplasma concentration versus time. Results are shown for the analysis of plasma
samples from subject 3.
Table 5
OAA and pyruvate PK parameters. Reported values aremean± standard deviation of individual patient values, with ranges in parentheses. Since no signiﬁcant differences or trends were
observed between the ﬁrst-dose and steady-state values for these patients the values from both PK days were included. N = total number of PK sample sets included.
Cmax, ng/ml Tmax, h Cmax/C0
OAA (n = 8) 551 ± 241 (210–1122) 1.2 ± 0.7 (0.5–2.5) 1.4 ± 0.5 (1.0–2.1)
Pyruvate (n = 10) 11,964 ± 7979 (3144–21,122) 2.1 ± 1.5 (0.5–4.0) 1.4 ± 0.8 (1.0–3.3)
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was reported in 1968 [14]. In that study the author tested the oral hypo-
glycemic effect of OAA in diabetic subjects and found it was well-
tolerated at doses ranging from 100 to 1000 mg per day (administered
in divided doses), and for durations ranging from 5 to 44 days (the
1000 mg per day dose was only tested for 5 days). Based on compari-
sons between pre and post-treatment fasting blood sugar levels, it was
concluded that OAA did have a hypoglycemic effect. While we did not
detect a similar effect, it is important tonote thatwe studiedAD subjects
who did not carry a diabetes diagnosis and had lower blood sugars, the
OAAdoseswe evaluatedwere lower than those tested in themajority of
the diabetic subjects, and the absolute glucose readings from visit 2
were slightly lower than the visit 1 readings in 5 of our 6 subjects.
The 1968 study also reported limited PK data. Levels were not in-
creased 30 min but were increased 60 min after 200 mg was orally
administered to three subjects. On average, blood OAA levels rose
from 0 ng/ml to 23 ng/ml. Clearly, both the basal and the peak OAA
concentrations we report here are far higher than those related in the
previous study. That study used differentmethods tomeasure OAA con-
centrations. No details were provided regarding the validation of the
method, including the speciﬁcity of the assay and the range of detection
and quantiﬁcation. Without knowledge of the validated speciﬁcity and
sensitivity of the previous analytical method we cannot compare the
measured values from the two studies, although we would assume
our LC–MS/MS approach should have greater sensitivity and speciﬁcity
than the derivatization and colorimetric approach described in the ear-
lier study.
In addition to being proposed for the treatment of AD and diabetes,
recent preclinical research has also identiﬁed OAA as a potential thera-
peutic agent for stroke, traumatic brain injury, amyotrophic lateral scle-
rosis, and glioma [15–18]. The clinical safety data we now report should
prove relevant to efforts intending to translate results from these pre-
clinical studies to the clinical arena. Our study also informs our attempts
to develop OAA as a treatment for AD. Overall, we conclude that al-
though OAA 100 mg capsules twice per day for one month are safe in
AD subjects, because a consistent and clear increase in the OAA plasma
level was not observed future clinical studies need to evaluate higher
doses.
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